Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human

Cancer Gene Therapy

Volumn 18, Issue 1, 2011, Pages 53-62

  Shahabi, V ^a   Seavey, M M ^b   MacIag, P C ^a   Rivera, S ^a   Wallecha, A ^a  

^a ADVAXIS INC   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

breast cancer; HER2 neu; immunotherapy; Listeria

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HYBRID PROTEIN; LISTERIA MONOCYTOGENES VACCINE; LISTERIOLYSIN O; LIVE VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BREAST CANCER; CD8+ T LYMPHOCYTE; COLORECTAL CANCER; CONTROLLED STUDY; EPITOPE MAPPING; GENE OVEREXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LISTERIA MONOCYTOGENES; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TRANSGENIC ANIMAL;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; LISTERIA MONOCYTOGENES; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RATS; RECEPTOR, ERBB-2; VACCINES, ATTENUATED;

ANIMALIA; LISTERIA; LISTERIA MONOCYTOGENES; MUS;

EID: 78650303947     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.48     Document Type: Article

References (29)

1. Reynolds A. Stereotactic breast biopsy: a review. Radiol Technol 2009; 80: 447M-464M.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
4. Singh R, Dominiecki ME, Jaffee EM, Paterson Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol 2005; 175: 3663-3673.
5. Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y et al. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 2009; 15: 924-932.
6. Wallecha A, Maciag PC, Rivera S, Paterson Y, Shahabi V. Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunother-apy. Clin Vaccine Immunol 2009; 16: 96-103.
7. Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000; 60: 3569-3576.
8. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167: 6471-6479.
9. Peters C, Paterson Y. Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts. Vaccine 2003; 21: 1187-1194.
10. Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 2008; 57: 1301-1313.
11. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
12. Singh R, Paterson Y. Immunoediting sculpts tumor epitopes during immunotherapy. Cancer Res 2007; 67: 1887-1892.
13. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999; 59: 431-435.
14. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999; 163: 1037-1044.
15. Verch T, Pan ZK, Paterson Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 2004; 72: 6418-6425.
16. Pegram M. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways Clin Breast Cancer 2008; 8(Suppl 3): S121-S130.
17. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B et al. Pathologic complete response to neoadju-vant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-2420.
18. 0 ssrA gene tag regulates the growth and virulence of racemase-deficient Listeria mono-cytogenes. Microbiology 2006; 152(Part 10): 3091-3102.
19. Thompson RJ, Bouwer HG, Portnoy DA, Frankel FR. Pathogenicity and immunogenicity of a Listeria monocyto-genes strain that requires D-alanine for growth. Infect Immun 1998; 66: 3552-3561.
20. Nitcheu-Tefit J, Dai MS, Critchley-Thorne RJ, Ramirez-Jimenez F, Xu M, Conchon S et al. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo. J Immunol 2007; 179: 1532-1541.
21. Nishikawa H, Tsuji T, Jager E, Briones G, Ritter G, Old LJ et al. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 2008; 111: 1404-1412.
22. Kim SH, Castro F, Paterson Y, Gravekamp C. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action. Cancer Res 2009; 69: 5860-5866.
23. Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunother-apeutics. Adv Appl Microbiol 2009; 66: 1-27.
24. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-910.
25. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine 2002; 20(Suppl 4): A40-A45. (Pubitemid 35449404)
26. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion mole-cule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111-1117.
27. Brown KA. Factors modifying the migration of lymphocytes across the blood-brain barrier. Int Immunopharmacol 2001; 1: 2043-2062.
28. Prins RM, Bruhn KW, Craft N, Lin JW, Kim CH, Odesa SK et al. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden. Neurosurgery 2006; 58: 169-178; discussion 169-178.
29. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase i safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009; 27: 3975-3983.